On March 28, 2023 Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, reported its annual report for 2022 (Press release, Herantis Pharma, MAR 28, 2023, View Source,c3741784 [SID1234629406]). The Annual Report contains financial statements and the report of the Board of Directors. The Annual Report is available in PDF format as appendix to this release and on Herantis Pharma’s website: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: [email protected]

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

Company website: www.herantis.com